Unchained Labs Explodes Into AI-Driven Automation, Launches Stuntman
Unchained Labs unveiled Stuntman, an AI‑driven automation platform that lets scientists command experiments using natural‑language prompts. The system embeds a large‑language model to translate plain‑text instructions into executable workflows while offering deep programmatic control when needed. Its modular hardware architecture can be reconfigured on the fly, delivering a flexible, open‑format data capture that streamlines experiment design and analysis. By removing coding bottlenecks, Stuntman promises faster iteration and reduced time‑to‑insight for life‑science research teams.
AI Reads Brain MRIs in Seconds and Flags Emergencies
University of Michigan researchers unveiled Prima, a vision‑language AI that reads brain MRIs in seconds and flags urgent cases. In a study of over 30,000 scans, Prima achieved 97.5% accuracy across more than 50 neurological diagnoses and could prioritize emergencies...
Parents of Medically Complex Children Face Significant Challenges with At-Home Medical Devices
A recent study by the Stanley Manne Children’s Research Institute, published in Pediatrics, reveals that parents of medically complex children face serious safety and usability issues with at‑home medical devices. Interviews with 17 caregivers highlighted device malfunctions, confusing interfaces, and...
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
Investment in radiopharmaceuticals is driving a fierce talent shortage as big‑pharma players like AstraZeneca, Novartis and Eli Lilly expand into the modality. The success of lutetium‑177 therapies such as Lutathera and Pluvicto has sparked a surge in clinical studies, intensifying demand...
Symptoms Impacting Health Quality in Swedish Older Men
Researchers published a cross‑sectional study in BMC Geriatrics examining symptom prevalence among Swedish men aged 65 and older and its impact on health‑related quality of life. The survey identified joint pain, fatigue, anxiety and depression as the most common complaints,...
Elevated Mortality Rates in Youth and Young Adults with Autism Spectrum Disorder, Intellectual Disability, or Cerebral Palsy
A JAMA Pediatrics study finds youth and young adults with autism, intellectual disability, or cerebral palsy face markedly higher mortality than peers. Standard death‑certificate coding severely under‑captures these deaths, creating hidden disparities. By linking alternative health data, researchers documented excess...
Modulated UV-C Light Increases the Shelf Life of Guavas, Study Shows
Researchers at Brazil's EMBRAPA have demonstrated that modulated UV‑C light—delivered in pulses rather than continuously—effectively suppresses anthracnose fungus on guavas, extending their post‑harvest shelf life. The treatment uses a cylindrical chamber with three strategically positioned UV‑C lamps that maximize surface...
Start-Up Funding, the Perils of Compounding, and Neuropsych Insights — a BioCentury Podcast
BioCentury reports that 2025 ended a four‑year decline in biotech series A financing, with 144 companies raising $8 billion. The “BioCentury This Week” podcast highlights which venture‑capital‑backed firms attracted capital and what the trends indicate for emerging technologies. Washington editor Steve Usdin...
Force-Induced Inter-Protofilament Gaps Can Pave the Way for Life in Microtubule Research
Researchers at the University of Hong Kong have shown that specific tubulin isotypes act as mechanical sensors, enabling force‑induced gaps between protofilaments in microtubules. These transient gaps open the otherwise sealed lumen, allowing luminal‑binding proteins to access the inner surface....
New Tool Cracks Microbial Defense Codes for Faster, Precise Bioengineering
Oak Ridge National Laboratory scientists have unveiled MIJAMP, open‑source software that maps DNA methylation patterns to neutralize microbial restriction‑modification defenses. By leveraging nanopore long‑read sequencing and pattern‑recognition algorithms, the tool cuts the time required to domesticate non‑model microbes from a...
Efficacy and Safety of Pharmacological Treatments in Borderline Personality Disorder: A Systematic Review and Network Meta-Analysis
A recent systematic review and network meta‑analysis evaluated the efficacy and safety of pharmacological interventions for borderline personality disorder (BPD). The analysis pooled data from randomized trials of antipsychotics, mood stabilizers, antidepressants, and novel agents, comparing them head‑to‑head using a...
Connectome-Based Growth Models Reveal Individual Heterogeneity and Neurophysiological Subtypes of Subthreshold Depression
The study applied connectome‑based normative modeling to 197 individuals with subthreshold depression (StD), revealing that 69% exhibit extreme functional connectivity deviations. Two neurophysiological subtypes emerged: Subtype 1 with pronounced positive deviations in default‑mode, limbic and subcortical networks and negative deviations in...
TMS in Adolescent Depression: A Milestone FDA Clearance
The FDA granted clearance for transcranial magnetic stimulation (TMS) as an adjunctive therapy for major depressive disorder in adolescents aged 15‑21, marking the first non‑pharmacologic device approval for this group. Clinical trials show response rates as high as 96‑98% when...
The Next Wave of Biotech Growth — a Perspective
Biotech investors have long chased scientific hype that rarely translated into commercial wins, often leaving value to large pharma. The article argues the next growth wave will stem from biotechs launching independent therapeutics that achieve meaningful sales, mirroring the early‑2010s...
![Single-Molecule SERS Gets Steadier as CB[7] Traps a 'Dancing' Molecule](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/a218bb91a3d27332f4ed8f925f30842c.webp)
Single-Molecule SERS Gets Steadier as CB[7] Traps a 'Dancing' Molecule
Researchers at the Institute of Physical Chemistry, Polish Academy of Sciences have demonstrated that encapsulating a single molecule within cucurbit[7]uril (CB[7]) stabilizes its surface‑enhanced Raman spectroscopy (SERS) signal. By forming a supramolecular complex with thionine dye, the CB[7] cage suppresses...
Bioengineers Build Branched, Perfusable Kidney Collecting Ducts Using 3D Bioprinting
Harvard SEAS and the Wyss Institute have engineered perfusable, branched kidney collecting‑duct networks using 3D bioprinting and stem‑cell‑derived organoids. The team created a collagen‑basement‑membrane matrix that supports iPSC differentiation into collecting‑duct cells and printed tubular structures that interconnect with a...
FDA Rejects Regenxbio's Hunter Syndrome Gene Therapy
The U.S. Food and Drug Administration has officially rejected Regenxbio's investigational gene therapy for Hunter syndrome, a severe X‑linked lysosomal storage disorder. The agency cited gaps in efficacy data and unresolved safety signals from the early‑stage clinical program. Regenxbio had...
DeepChopper Model Improves RNA Sequencing Research by Mitigating Chimera Artifacts
Scientists led by Rendong Yang at Northwestern University unveiled DeepChopper, a genomic large‑language model designed to detect and remove chimera artifacts in nanopore direct RNA sequencing. The tool operates with single‑nucleotide resolution across long reads, dramatically improving the accuracy of...
With Scant Data, RFK Jr. Credits Trump for Higher European Drug Prices
Robert F. Kennedy Jr., serving as HHS Secretary, reiterated his claim that President Donald Trump's personal intervention and the threat of tariffs forced European nations to raise drug prices. He offered no empirical evidence to substantiate the assertion, and analysts...
Nanodevice Tugs Single Proteins to Reveal How Cells Sense Force
Yale researchers have created a DNA‑based nanodevice that can tug on individual proteins with piconewton precision. The U‑shaped frame clamps a protein via DNA handles that fold to apply controlled tension. Using talin as a test case, the device reproduced...
Hybrid Cryomicroneedles Enhance DC Vaccine Efficacy and Function as Non‐Typical Artificial Tertiary Lymphoid Structures to Provide Neuroprotective Immunity in Spinal...
Researchers have engineered hybrid cryomicroneedle patches (pG/DL@npDC‑cryoMNs) that embed a neuroprotective dendritic cell vaccine within a methacrylated decellularized lymph‑node matrix and porous GelMA hydrogel. The device rapidly releases viable npDCs, triggers a strong CD4⁺ T‑cell response, and forms a non‑typical...
Fresenius Kabi and Phlow Corp. Enter First US End-to-End Manufacturing Collaboration
Fresenius Kabi and Phlow Corp. have launched the United States’ first end‑to‑end domestic manufacturing collaboration for epinephrine injection, pairing Phlow’s new API production facility in Virginia with Fresenius Kabi’s existing formulation and fill sites. The partnership includes an FDA‑filed Drug...
Despite FDA’s Crackdown, Pharma Is Still Spending Millions on Ads
The FDA launched an aggressive crackdown on pharmaceutical advertising last fall, issuing thousands of warning letters to drugmakers over misleading consumer ads. Despite the heightened scrutiny, the industry continued to pour roughly $2 billion into promotional campaigns, shifting spend toward digital...
Hims & Hers Stock Crashes After FDA Announces Plans to Take 'Decisive Steps' Against GLP-1 Compounds
Hims & Hers shares plunged up to 27% after the FDA announced it will take decisive steps to restrict non‑FDA‑approved compounded GLP‑1 active pharmaceutical ingredients. The regulator’s move coincides with a lawsuit from Novo Nordisk seeking to block Hims &...
Galux Raises $29M Series B; CSL Teams up with Memo
South Korean biotech Galux secured $29 million in a Series B round to accelerate its AI‑driven research platform that designs novel protein therapeutics. The funding, led by regional venture partners, will expand Galux’s computational pipeline and scale up pre‑clinical collaborations. In parallel,...
Simple At-Home Tests Strips Can Detect Cat and Dog Viruses
Researchers have unveiled a hand‑warm, DNA‑based lateral‑flow strip that detects feline parvovirus (FPV) and canine parvovirus (CPV) with 100 % sensitivity in clinic samples. The assay amplifies the VP2 gene in about 35 minutes, then displays a red line on a...
#ACTRIMS26: Roche’s MS Drug Fenebrutinib Beats Ocrevus, Cutting Risk of Disability Progression by 12%
Roche announced that its Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib achieved non‑inferior efficacy to the company’s blockbuster Ocrevus in a Phase 3 trial for primary progressive multiple sclerosis (PPMS). The oral agent lowered the risk of confirmed disability progression by 12%...
Briya Appoints Brian Creighton to Boost Growth in AI-Driven Healthcare Data
Briya, a health‑AI firm, announced Brian Creighton as Executive Director of Client Strategy to accelerate its U.S. expansion. Creighton brings more than two decades of medical imaging and AI sales experience, most recently as VP of Sales at Merative. He...
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
The breast‑cancer pipeline is heating up as several late‑stage candidates demonstrate significant efficacy across sub‑types. Roche’s oral SERD giredestrant cut invasive disease recurrence by 30% in early‑stage ER‑positive patients, while AstraZeneca’s camizestrant combined with a CDK4/6 inhibitor reduced progression risk...
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Biogen expects Phase 2 readout for its tau‑targeting antisense oligonucleotide BIIB080 in the second or third quarter of 2026. The CELIA trial evaluates three dose levels through week 76 and uses cognition as the primary endpoint. A positive signal could lift Biogen’s...
Takeda, Iambic Sign Multiyear R&D Deal for AI Drug Discovery
Takeda Pharmaceutical announced a multi‑year research agreement with San Diego biotech Iambic to develop AI‑driven small‑molecule drug candidates. The collaboration merges Takeda’s therapeutic expertise with Iambic’s generative AI platform to accelerate hit identification and lead optimization. Joint R&D labs, data...
Takeda, Iambic Partner in Latest Pharma AI Push
Japan’s largest drugmaker Takeda has signed a multiyear agreement with AI specialist Iambic Therapeutics, potentially worth more than $1.7 billion. The partnership grants Takeda access to Iambic’s AI‑driven drug discovery platform and a protein‑receptor interaction model, targeting small‑molecule treatments for cancer,...
New Diagnostics Define Drug Targets for Alzheimer’s, Parkinson’s and Beyond
Amprion Diagnostics has commercialized a seed‑amplification assay, SAAmplify‑αSYN, that detects misfolded alpha‑synuclein in cerebrospinal fluid, earning FDA breakthrough‑device status in 2019. The test can identify Parkinson’s, Lewy‑body dementia and up to half of Alzheimer’s cases years before clinical symptoms appear....
Liver Toxicities Force Pause on Two Dose Groups of UniQure’s Mid-Stage Fabry Study
UniQure paused dosing in the mid- and high-dose arms of its Phase 1/2a Fabry gene‑therapy trial after two patients experienced grade 3 liver enzyme elevations. The affected cohorts received 4 × 10¹³ and 6 × 10¹³ genome copies per kilogram of AMT‑191, while the low‑dose group...
Data Builds on Roche's Dominance in Primary Progressive MS
Roche disclosed phase 3 data showing its oral BTK inhibitor fenebrutinib is non‑inferior to Ocrevus in primary progressive multiple sclerosis (PPMS). The FENtrepid trial demonstrated a 12% relative reduction in disability progression risk over 24 weeks, with a notable 26% improvement...
Ultragenyx’s Gene Therapy Shows Long-Term Efficacy in Two Sanfilippo Studies
Ultragenyx reported that its investigational AAV gene therapy UX111 delivers sustained cognitive improvements in Sanfilippo A patients, with follow‑up extending up to 8.5 years. Data from 33 dosed participants—27 receiving the highest dose—showed a 23.3‑point gain on the Bailey‑III scale...
Novo Nordisk Sues Hims over Wegovy Patent Infringement, Considers Seeking 'Hundreds of Millions' In Damages
Novo Nordisk has filed a federal lawsuit against Hims Inc., alleging that the company infringed on patents covering Wegovy, Novo's flagship semaglutide obesity treatment. The complaint seeks damages in the “hundreds of millions” of dollars, reflecting the high commercial stakes...
Hengrui, Kailera Tout Positive Results for Dual-Acting Obesity Pill
Hengrui Pharma and Kailera Therapeutics reported Phase 2 results for oral ribupatide, a dual GLP‑1/GIP obesity pill. In a 166‑patient, 26‑week study the drug produced an average 12 % weight loss versus 2 % for placebo, with over half of high‑dose participants shedding...
Novartis Breaks Ground on San Diego Biomedical R&D Site
Novartis has broken ground on a $1.1 billion, 466,000‑sq‑ft biomedical research centre in San Diego, the flagship of a $23 billion U.S. capital investment programme. The campus, slated to open around 2029, will house roughly 1,000 scientists and integrate the company’s West...
Making AI Work, MIT Technology Review’s New AI Newsletter, Is Here
MIT Technology Review has launched "Making AI Work," a limited‑run, seven‑week AI mini‑course newsletter that delivers weekly case studies on real‑world AI deployments. The series spans health care, nuclear energy, education, small‑business operations, finance and personal productivity, ending with a...
NIH Director Says No Studies Link Vaccines and Autism, Outlines Modernization
NIH Director Jay Bhattacharya told the Senate HELP Committee that no scientific study links any vaccine to autism, reaffirming the consensus after senators raised vaccine‑safety concerns. He used the hearing to unveil a modernization agenda that includes centralizing peer review,...
CDC Traveler-Based Genomic Surveillance Program Tops One Million Participants, Giving Clinical Labs Earlier Warning on Emerging Variants
The CDC’s Traveler‑Based Genomic Surveillance (TGS) program has crossed the one‑million‑volunteer threshold, marking a major expansion of upstream pathogen monitoring at U.S. airports. Launched in 2021, TGS combines anonymous nasal swabs from international arrivals with aircraft wastewater sampling, leveraging public‑private...
Kaster Technologies Raises $1.6 Million to Scale up Pharma Manufacturing
Canadian startup Kaster Technologies announced a CAD 1.6 million pre‑seed round led by Graphite Ventures, with participation from Hidden Layers Capital and angel investor Louis‑Martin Rousseau. The company offers an AI‑guided software platform that optimizes pharmaceutical production cycles, promising up to...
Navigating the Complexities of Cell and Gene Therapy Supply Chains
Cell and gene therapies (CGTs) promise breakthrough treatments but demand highly complex supply chains. The process spans cell collection, manufacturing, temperature‑controlled transport, and delivery, requiring strict regulatory compliance and real‑time data integrity. Developers face challenges such as cold‑chain logistics, stakeholder...
BullFrog AI to Unveil New Precision AI Capability
BullFrog AI announced a new scenario‑based decision engine to be released on March 25, adding a strategic layer to its bfPREP™ and bfLEAP® platforms. The engine compares drug programs, indications, and trial designs without forcing single numeric scores, and evaluates portfolio...
Zydus Lifesciences Posts 30% Revenue Jump in Q3, Net Profit up 9%
Zydus Lifesciences reported a 30% year‑on‑year revenue increase to ₹68.6 bn in Q3 FY2025‑26, driven by strong performance across pharmaceuticals, consumer wellness and medtech. Adjusted net profit rose 9% to ₹11.1 bn, while EBITDA grew 31% to ₹18.2 bn, lifting margins to 26.5%....
Strong Clinical Data for Breye Lead Asset Danegaptide
Breye Therapeutics presented early-phase data on its oral small‑molecule danegaptide for non‑proliferative diabetic retinopathy (NPDR). In a multi‑centre phase 1b study of 24 patients, the drug was well tolerated and achieved plasma concentrations within the target range. More than half of...
Lilly Returns to Innovent to Partner on Cancer and Immune Diseases
Eli Lilly has deepened its alliance with China‑based Innovent Biologics, signing a new agreement that includes a $350 million upfront payment. The partnership will focus on co‑developing bispecific antibody candidates targeting oncology and immunology indications. Both companies will share development costs, milestone...
Biotech Startup Pandorum Technologies Raises $18 Mn in Series B Round
Pandorum Technologies, an Indian‑US biotech focused on exosome‑based regenerative therapies, closed an $18 million Series B round led by Protons Corporate. The round, completed in two tranches, values the company at roughly $91 million post‑money, bringing total capital raised to about $43 million. Proceeds...
Elevate Now Raises Rs 18 Cr in Seed Round Led by Physis Capital
Elevate Now, a doctor‑led clinical weight‑loss platform, secured Rs 18 crore in a seed round headed by Physis Capital, with Inflection Point Ventures and Titan Capital also participating. The Bengaluru startup previously raised $2 million in a pre‑seed round from W Health Ventures,...
